Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | HPGD | P15428 | 4/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | NOS3 | P29474 | 2/20 | 0.35 |
| ▸ | NOS2 | P35228 | 2/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.33 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.33 |
| ▸ | LTK | P29376 | 1/20 | 0.33 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.33 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.33 |
| ▸ | CDK8 | P49336 | 1/20 | 0.33 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.33 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1868060 | 0.79 | ALDH1A1 (0.36) | MEN1KMT2AMAPTALDH1A1HPGD | |
| SCHEMBL3081411 | 0.78 | ALDH1A1 (0.38) | MEN1KMT2AMAPTALDH1A1HPGD | |
| SCHEMBL9211141 | 0.77 | ALDH1A1 (0.47) | MEN1KMT2AMAPTALDH1A1HPGD | |
| SCHEMBL3619022 | 0.76 | ALDH1A1 (0.36) | MEN1KMT2AMAPTALDH1A1HPGD | |
| SCHEMBL4103011 | 0.75 | ALDH1A1 (0.37) | MEN1KMT2AMAPTALDH1A1HPGD | |
| SCHEMBL11708484 | 0.75 | HPGD (0.37) | MEN1KMT2AMAPTALDH1A1HPGD | |
| SCHEMBL8735560 | 0.75 | ALDH1A1 (0.36) | MEN1KMT2AMAPTALDH1A1HPGD | |
| SCHEMBL10435536 | 0.72 | KDM4E (0.35) | MEN1KMT2AMAPTALDH1A1HPGD | |
| SCHEMBL27528131 | 0.71 | KDM4E (0.33) | ALDH1A1HPGDKDM4E | |
| SCHEMBL27272787 | 0.71 | ALDH1A1 (0.37) | MEN1KMT2AMAPTALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6679923-B2 | HAIR DYEING FORMULATION CONTAINING PYRAZOLIN-4,5-DIONES AND AT LEAST ONE AROMATIC PRIMARY AMINE ENABLES THE DYEING OF KERATIN FIBERS WITHOUT AND OXIDIZING AGENT IN SHADES WHICH ARE STRONG, VARIED, RESISTANT AND LESS SELECTIVE | L'OREAL S.A. (FR) | 2004-01-20 | — | — | US | claimed |
| US-20020194685-A1 | Composition for dyeing keratin fibres, comprising a pyrazoline-4, 5-dione and an aromatic primary amine | L'OREAL S.A. (FR) | 2002-12-26 | — | — | US | claimed |
| US-6464732-B2 | HAIR DYE MIXTURE | L'OREAL S.A. (FR) | 2002-10-15 | — | — | US | claimed |
| US-20020040508-A1 | COMPOSITION FOR DYEING KERATIN FIBRES,COMPRISING A PYRAZOLIN-4,5-DIONE AND AN AROMATIC PRIMARY AMINE | L'OREAL S.A. (FR) | 2002-04-11 | — | — | US | claimed |
| EP-0981320-A1 | COMPOSITION FOR DYEING KERATIN FIBRES COMPRISING A PYRAZOLIN-4,5-DIONE AND AN AROMATIC PRIMARY AMINE | L'OREAL (FR) | 2000-03-01 | — | — | EP | claimed |
| WO-1998051268-A1 | COMPOSITION FOR DYEING KERATIN FIBRES COMPRISING A PYRAZOLIN-4,5-DIONE AND AN AROMATIC PRIMARY AMINE | L'OREAL (FR) | 1998-11-19 | — | — | WO | claimed |
| CN-115335373-B | Compounds and uses thereof | 福宏治疗公司 | 2025-05-20 | — | — | CN | disclosed |
| CN-115335373-A | Compound and use thereof | 福宏治疗公司 | 2022-11-11 | — | — | CN | disclosed |
| US-8420634-B2 | Amidine, thiourea and guanidine derivatives of 2-aminobenzothiazoles and aminobenzothiazines for their use as pharmacological agents for the treatment of neurodegenerative pathologies | ROTTAPHARM S.P.A. (IT) | 2013-04-16 | — | — | US | disclosed |
| US-8420634-B2 | Amidine, thiourea and guanidine derivatives of 2-aminobenzothiazoles and aminobenzothiazines for their use as pharmacological agents for the treatment of neurodegenerative pathologies | ROTTAPHARM S.P.A. (IT) | 2013-04-16 | — | — | US | disclosed |
| US-20100197670-A1 | AMIDINE, THIOUREA AND GUANIDINE DERIVATIVES OF 2-AMINOBENZOTHIAZOLES AND AMINOBENZOTHIAZINES FOR THEIR USE AS PHARMACOLOGICAL AGENTS FOR THE TREATMENT OF NEURODEGENERATIVE PATHOLOGIES | ROTTAPHARM BIOTECH S.R.L. (IT) | 2010-08-05 | — | — | US | disclosed |
| EP-2190829-A2 | AMIDINE, THIOUREA AND GUANIDINE DERIVATIVES OF 2-AMINOBENZOTHIAZOLES AND AMINOBENZOTHIAZINES FOR THEIR USE AS PHARMACOLOGICAL AGENTS FOR THE TREATMENT OF NEURODEGENERATIVE PATHOLOGIES | Rottapharm S.p.A. (IT) | 2010-06-02 | — | — | EP | disclosed |
| WO-2009040331-A2 | AMIDINE, THIOUREA AND GUANIDINE DERIVATIVES OF 2-AMINOBENZOTHIAZOLES AND AMINOBENZOTHIAZINES FOR THEIR USE AS PHARMACOLOGICAL AGENTS FOR THE TREATMENT OF NEURODEGENERATIVE PATHOLOGIES | ROTTAPHARM S.P.A. (IT) | 2009-04-02 | — | — | WO | disclosed |
| EP-0461182-A1 | THERMALLY STABLE FORMS OF ELECTRICALLY CONDUCTIVE POLYANILINE. | ALLIED SIGNAL INC (US) | 1991-12-18 | — | — | EP | disclosed |
| US-5069820-A | DOPED WITH ORGANIC SULFONATE | ALLIED-SIGNAL INC. (US) | 1991-12-03 | — | — | US | disclosed |
| WO-1990010297-A1 | THERMALLY STABLE FORMS OF ELECTRICALLY CONDUCTIVE POLYANILINE | ALLIED-SIGNAL INC. (US) | 1990-09-07 | — | — | WO | disclosed |
| EP-0380517-A1 | THERMALLY STABLE FORMS OF ELECTRICALLY CONDUCTIVE POLYANILINE. | ALLIED SIGNAL INC (US) | 1990-08-08 | — | — | EP | disclosed |
| CN-1032660-A | The sulfonylurea derivatives of weeding | ICI AUSTRALIA OPERATIONS (AU) | 1989-05-03 | — | — | CN | disclosed |
| EP-0313311-A2 | Herbicidal sulfonamides | ICI AUSTRALIA OPERATIONS PROPRIETARY LIMITED (AU) | 1989-04-26 | — | — | EP | disclosed |
| WO-1989001694-A1 | THERMALLY STABLE FORMS OF ELECTRICALLY CONDUCTIVE POLYANILINE | ALLIED-SIGNAL INC. (US) | 1989-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197670-A1 | AMIDINE, THIOUREA AND GUANIDINE DERIVATIVES OF 2-AMINOBENZOTHIAZOLES AND AMINOBENZOTHIAZINES FOR THEIR USE AS PHARMACOLOGICAL AGENTS FOR THE TREATMENT OF NEURODEGENERATIVE PATHOLOGIES | ABAT, SMN1; SMN2, IAPP | MEN1 2399/4885KMT2A 3810/4885MAPT 12/4885 |
| US-20020194685-A1 | Composition for dyeing keratin fibres, comprising a pyrazoline-4, 5-dione and an aromatic primary amine | KRT18, KLK5, MARK1 | MEN1 3401/4885KMT2A 1376/4885MAPT 591/4885 |
| US-20020040508-A1 | COMPOSITION FOR DYEING KERATIN FIBRES,COMPRISING A PYRAZOLIN-4,5-DIONE AND AN AROMATIC PRIMARY AMINE | KRT18, KLK5, H1-5 | MEN1 3896/4885KMT2A 1176/4885MAPT 562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.